Lcn2-Derived Anticalins for CD98hc Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer theranostics lack specific recognition and targeting of the cluster of differentiation 98 heavy chain (CD98hc), leading to inadequate diagnostic imaging and therapeutic efficacy due to poor tissue penetration and pharmacokinetics of existing antibodies.
Innovation Solution
Development of a CD98hc-specific binding protein derived from lipocalin 2 (Lcn2), known as Anticalins, which binds to CD98hc with a dissociation constant (KD) of 200 nM or lower, offering high specificity and tissue penetration, and can be labeled for imaging or conjugated for therapeutic purposes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antibodies are used for targeting CD98hc, then specific recognition of the target is achieved, but tissue penetration and pharmacokinetics are poor
Solution Approach 1:
The invention extracts only the essential binding function from traditional antibodies by using minimized binding proteins (single-domain antibodies or antibody fragments). These extracted binding domains maintain target specificity while eliminating the structural constraints that limit tissue penetration, achieving fast tissue penetration rates comparable to small molecules.
Solution Approach 2:
The invention creates simplified copies of antibody binding functionality using non-immunoglobulin scaffolds such as nanobodies, DARPins, or affibodies. These copied binding functions replicate the target recognition capability while adopting smaller, more penetrative structural forms that can access deep tissue compartments effectively.
2Measurement precision
If traditional antibodies are used for diagnostic imaging, then target detection capability is provided, but imaging contrast is low due to slow pharmacokinetics
Solution Approach 1:
The invention employs short-lived, rapidly cleared binding protein formats that function effectively for diagnostic imaging but are quickly eliminated from the system. This rapid clearance reduces background signal and improves imaging contrast, allowing effective target detection within an optimized time window while minimizing prolonged exposure.
Solution Approach 2:
The invention uses dynamically optimized binding proteins with tunable pharmacokinetic properties. By adjusting the size, charge, and structural characteristics of the binding domains, the system achieves rapid tissue penetration followed by controlled circulation and clearance, optimizing the time profile for diagnostic imaging applications.
3Speed
If small molecule inhibitors are used for targeting CD98hc, then tissue penetration is improved, but specificity is reduced
Solution Approach 1:
The invention creates composite molecular structures that combine the small size and tissue penetration capability of small molecules with the high specificity of protein-based binders. The minimized binding proteins serve as hybrid entities that penetrate tissue like small molecules but maintain protein-level target recognition precision through structured binding interfaces.
Solution Approach 2:
The invention optimizes multiple parameters simultaneously - reducing molecular size for penetration while maintaining binding affinity and specificity through engineered binding domains. By adjusting parameters such as domain size, charge distribution, and binding interface composition, the system achieves both rapid tissue penetration and high target specificity.
Data Source
AI summary
The present invention relates to a cluster of differentiation 98 heavy chain (CD98hc)-specific binding protein, wherein the CD98hc-specific binding protein is a lipocalin 2 (Lcn2)-derived binding protein and binds to CD98hc with a KD of 200 nM or lower.